M&T Bank Corp Akebia Therapeutics, Inc. Transaction History

M&T Bank Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 06, 2020	SELL	$2.39 - $13.08 $110,241 - $603,328	-46,126 Closed	0 $0
Q2 2020 Jul 29, 2020	BUY	$6.67 - $13.58 $62,164 - $126,565	9,320 Added 25.32%	46,126 $627,000
Q1 2020 May 14, 2020	BUY	$4.1 - $10.24 $49,257 - $123,023	12,014 Added 48.46%	36,806 $279,000
Q4 2019 Feb 07, 2020	BUY	$3.16 - $6.73 $19,184 - $40,857	6,071 Added 32.43%	24,792 $157,000
Q3 2019 Nov 12, 2019	BUY	$3.55 - $5.4 $14,959 - $22,755	4,214 Added 29.05%	18,721 $74,000
Q2 2019 Aug 12, 2019	BUY	$4.1 - $8.05 $11,865 - $23,296	2,894 Added 24.92%	14,507 $71,000
Q1 2019 May 15, 2019	BUY	$5.41 - $8.73 $62,826 - $101,381	11,613 New	11,613 $96,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $417M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.